Cardiac sodium channelopathies

Ahmad S Amin, Alaleh Asghari-Roodsari, Hanno L Tan, Ahmad S Amin, Alaleh Asghari-Roodsari, Hanno L Tan

Abstract

Cardiac sodium channel are protein complexes that are expressed in the sarcolemma of cardiomyocytes to carry a large inward depolarizing current (INa) during phase 0 of the cardiac action potential. The importance of INa for normal cardiac electrical activity is reflected by the high incidence of arrhythmias in cardiac sodium channelopathies, i.e., arrhythmogenic diseases in patients with mutations in SCN5A, the gene responsible for the pore-forming ion-conducting alpha-subunit, or in genes that encode the ancillary beta-subunits or regulatory proteins of the cardiac sodium channel. While clinical and genetic studies have laid the foundation for our understanding of cardiac sodium channelopathies by establishing links between arrhythmogenic diseases and mutations in genes that encode various subunits of the cardiac sodium channel, biophysical studies (particularly in heterologous expression systems and transgenic mouse models) have provided insights into the mechanisms by which INa dysfunction causes disease in such channelopathies. It is now recognized that mutations that increase INa delay cardiac repolarization, prolong action potential duration, and cause long QT syndrome, while mutations that reduce INa decrease cardiac excitability, reduce electrical conduction velocity, and induce Brugada syndrome, progressive cardiac conduction disease, sick sinus syndrome, or combinations thereof. Recently, mutation-induced INa dysfunction was also linked to dilated cardiomyopathy, atrial fibrillation, and sudden infant death syndrome. This review describes the structure and function of the cardiac sodium channel and its various subunits, summarizes major cardiac sodium channelopathies and the current knowledge concerning their genetic background and underlying molecular mechanisms, and discusses recent advances in the discovery of mutation-specific therapies in the management of these channelopathies.

Figures

Fig. 1
Fig. 1
The cardiac electrical activity and cardiac ion currents. a The electrical activity of the heart is represented on the surface electrocardiogram (ECG), and results from coordinated action potential generation in individual cardiomyocytes. The electrical activity starts by the spontaneous generation of action potentials in pacemaker cells in the sinoatrial node. Propagation of these action potentials creates an excitation wave through the atria, leading to atrial depolarization. After traveling through the atrioventricular node, the excitation wave reaches the ventricles, and leads to ventricular depolarization. b The cardiac action potential is generated by transmembrane inwardly and outwardly directed ion currents. The inward (depolarizing) sodium and calcium currents are pointed downwards and colored blue. The outward (repolarizing) potassium currents are pointed upwards and colored green
Fig. 2
Fig. 2
Molecular structure of the cardiac sodium channel. a Cartoon of the α-subunit (Nav1.5) and the β-subunit of the cardiac sodium channel. Nav1.5 consists of four domains (DI–DIV), each containing six transmembrane segments (S1–S6); S4 segments are positively charged and act as voltage sensors. The β-subunit consists of one single transmembrane segment. b The four domains of Nav1.5 fold around an ion-conducting pore, which is lined by the loops between the S5 and S6 segments. The expression and function of Nav1.5 is regulated by β-subunits and several directly or indirectly interacting regulatory proteins
Fig. 3
Fig. 3
Voltage-dependent activation and inactivation of the cardiac sodium channel. a Using the patch-clamp technique, the membrane potential dependence of activation is studied by applying 50 ms depolarizing voltage steps from a holding potential of −120 mV (inset). The activation curve is obtained by dividing the amplitude of the resulting sodium current at each voltage step by the maximum peak sodium current amplitude, and plotting versus the corresponding voltage. b The membrane potential dependence of inactivation is studied by applying 500 ms depolarizing voltage steps from a holding potential of −120 mV to inactivate the channels (prepulse). Next, the fraction of channels that is not inactivated by the prepulse is measured by applying a voltage step to 20 mV (test pulse). The inactivation curve is obtained by dividing the amplitude of sodium current at each test pulse by the maximum peak sodium current amplitude, and plotting versus the corresponding prepulse voltage. c The window current (gray area) arises when the sarcolemma reaches a potential that is depolarized sufficiently to reactivate some channels, but not enough to cause complete inactivation. d The voltage range for the window current is normally narrow and achieved during phase 3 of the ventricular action potential
Fig. 4
Fig. 4
Long QT syndrome type 3. a Prolonged QT intervals on the surface ECG of an individual with LQT-3. b QT interval prolongation results from delayed repolarization of ventricular action potentials. c Delayed repolarization in LQT-3 is often due to the presence of abnormal sustained non-inactivating sodium current (green area). d Sustained current results from incomplete inactivation of the sodium channels (green circles)
Fig. 5
Fig. 5
Alternative mechanisms of sodium channel gain-of-function in long QT syndrome type 3. a Increased window current due to delayed inactivation of cardiac sodium channels (green circles). Increased windows current is carried at potentials corresponding to phases 2 and 3 of the ventricular action potential (green area), remote from the peak sodium current during phase 0 (blue area). b Slower inactivation creates a late sodium current (green area). c Increased peak sodium current
Fig. 6
Fig. 6
Brugada syndrome. a Coved-type ST segment elevation in the right-precordial ECG leads V1 and V2 after intravenous (i.v.) administration of sodium channel blocking drug ajmaline in an individual with BrS. b BrS-linked SCN5A mutations often lead to peak sodium current reduction. c Reduced peak sodium current decreases the upstroke velocity of action potential phase 0, which slows cardiac electrical conduction
Fig. 7
Fig. 7
Mechanisms of sodium channel loss-of-function in Brugada syndrome, progressive cardiac conduction disease, and sick sinus syndrome. a Decreased sarcolemmal expression of Nav1.5 due to premature degradation of mutant channel proteins by the quality control system in the endoplasmic reticulum. b Delayed activation of cardiac sodium channels (red circles). c Earlier inactivation of cardiac sodium channels (red circles)
Fig. 8
Fig. 8
Prolonged conduction parameters (P wave, PR and QRS intervals), and right bundle branch block in an individual with progressive cardiac conduction disease
Fig. 9
Fig. 9
Sinus arrest in an individual with sick sinus syndrome. The patient also suffered from sinus bradycardia

References

    1. Abriel H, Kass RS. Regulation of the voltage-gated cardiac sodium channel Nav1.5 by interacting proteins. Trends Cardiovasc Med. 2005;15:35–40. doi: 10.1016/j.tcm.2005.01.001.
    1. Albert CM, Nam EG, Rimm EB, Jin HW, Hajjar RJ, Hunter DJ, MacRae CA, Ellinor PT. Cardiac sodium channel gene variants and sudden cardiac death in women. Circulation. 2008;117:16–23. doi: 10.1161/CIRCULATIONAHA.107.736330.
    1. Amin AS, de Groot EAA, Ruijter JM, Wilde AA, Tan HL. Exercise-induced ECG changes in Brugada syndrome. Circ Arrhythmia Electrophysiol. 2009;2:531–539. doi: 10.1161/CIRCEP.109.862441.
    1. Amin AS, Meregalli PG, Bardai A, Wilde AA, Tan HL. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med. 2008;149:216–218.
    1. Amin AS, Tan HL, Wilde AAM. Cardiac ion channels in health and disease. Heart Rhythm. 2009
    1. Amin AS, Verkerk AO, Bhuiyan ZA, Wilde AA, Tan HL. Novel Brugada syndrome-causing mutation in ion-conducting pore of cardiac Na+ channel does not affect ion selectivity properties. Acta Physiol Scand. 2005;185:291–301.
    1. Antzelevitch C. Cellular basis for the repolarization waves of the ECG. Ann N Y Acad Sci. 2006;1080:268–2681. doi: 10.1196/annals.1380.021.
    1. Arnestad M, Crotti L, Rognum TO, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Wang DW, Rhodes TE, George AL, Jr, Schwartz PJ. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation. 2007;115:361–367. doi: 10.1161/CIRCULATIONAHA.106.658021.
    1. Balser JR. The cardiac sodium channel: gating function and molecular pharmacology. J Mol Cell Cardiol. 2001;33:599–613. doi: 10.1006/jmcc.2000.1346.
    1. Bankston JR, Kass RS. Molecular determinants of local anesthetic action of beta-blocking drugs: implications for therapeutic management of long QT syndrome variant 3. J Mol Cell Cardiol. 2009
    1. Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I, Medina A. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation. 2000;101:1698–1706.
    1. Benito B, Brugada R, Perich RM, Lizotte E, Cinca J, Mont L, Berruezo A, Tolosana JM, Freixa X, Brugada P, Brugada J. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. Heart Rhythm. 2008;5:1434–1440. doi: 10.1016/j.hrthm.2008.07.013.
    1. Bennett PB, Yazawa K, Makita N, George AL., Jr Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995;376:683–685. doi: 10.1038/376683a0.
    1. Benson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ, Rhodes TH, George AL., Jr Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A) J Clin Invest. 2003;112:1019–1028.
    1. Bezzina C, Veldkamp MW, van Den Berg MP, Postma AV, Rook MB, Viersma JW, van Langen IM, Tan-Sindhunata G, Bink-Boelkens MT, van Der Hout AH, Mannens MM, Wilde AA. A single Na+ channel mutation causing both long-QT and Brugada syndromes. Circ Res. 1999;85:1206–1213.
    1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20:1391–1396. doi: 10.1016/0735-1097(92)90253-J.
    1. Charpentier F, Bourgé A, Mérot J. Mouse models of SCN5A-related cardiac arrhythmias. Prog Biophys Mol Biol. 2008;98:230–237. doi: 10.1016/j.pbiomolbio.2008.10.012.
    1. Chen LY, Ballew JD, Herron KJ, Rodeheffer RJ, Olson TM. A common polymorphism in SCN5A is associated with lone atrial fibrillation. Clin Pharmacol Ther. 2007;81:35–41. doi: 10.1038/sj.clpt.6100016.
    1. Clancy CE, Tateyama M, Liu H, Wehrens XH, Kass RS. Non-equilibrium gating in cardiac Na+ channels: an original mechanism of arrhythmia. Circulation. 2003;107:2233–2237. doi: 10.1161/.
    1. Cronk LB, Ye B, Kaku T, Tester DJ, Vatta M, Makielski JC, Ackerman MJ. Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. Heart Rhythm. 2007;4:161–166. doi: 10.1016/j.hrthm.2006.11.030.
    1. Dumaine R, Towbin JA, Brugada P, Vatta M, Nesterenko DV, Nesterenko VV, Brugada J, Brugada R, Antzelevitch C. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res. 1999;85:803–809.
    1. Dun W, Boyden PA. The Purkinje cell; 2008 style. J Mol Cell Cardiol. 2008;45:617–624. doi: 10.1016/j.yjmcc.2008.08.001.
    1. Ellinor PT, Nam EG, Shea MA, Milan DJ, Ruskin JN, MacRae CA. Cardiac sodium channel mutation in atrial fibrillation. Heart Rhythm. 2008;5:99–105. doi: 10.1016/j.hrthm.2007.09.015.
    1. Frustaci A, Priori SG, Pieroni M, Chimenti C, Napolitano C, Rivolta I, Sanna T, Bellocci F, Russo MA. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation. 2005;112:3680–3687. doi: 10.1161/CIRCULATIONAHA.105.520999.
    1. Ge J, Sun A, Paajanen V, Wang S, Su C, Yang Z, Li Y, Wang S, Jia J, Wang K, Zou Y, Gao L, Wang K, Fan Z. Molecular and clinical characterization of a novel SCN5A mutation associated with atrioventricular block and dilated cardiomyopathy. Circ Arrhythmia Electrophysiol. 2008;1:83–92. doi: 10.1161/CIRCEP.107.750752.
    1. Grant AO, Carboni MP, Neplioueva V, Starmer CF, Memmi M, Napolitano C, Priori S. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J Clin Invest. 2002;110:1201–1209.
    1. Haïssaguerre M, Extramiana F, Hocini M, Cauchemez B, Jaïs P, Cabrera JA, Farré J, Leenhardt A, Sanders P, Scavée C, Hsu LF, Weerasooriya R, Shah DC, Frank R, Maury P, Delay M, Garrigue S, Clémenty J. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation. 2003;108:925–928. doi: 10.1161/01.CIR.0000088781.99943.95.
    1. Hesse M, Kondo CS, Clark RB, Su L, Allen FL, Geary-Joo CT, Kunnathu S, Severson DL, Nygren A, Giles WR, Cross JC. Dilated cardiomyopathy is associated with reduced expression of the cardiac sodium channel Scn5a. Cardiovasc Res. 2007;75:498–509. doi: 10.1016/j.cardiores.2007.04.009.
    1. Hu D, Barajas-Martinez H, Burashnikov E, Springer M, Wu Y, Varro A, Pfeiffer R, Koopmann TT, Cordeiro JM, Guerchicoff A, Pollevick GD, Antzelevitch C. A mutation in the β3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet. 2009;2:270–278. doi: 10.1161/CIRCGENETICS.108.829192.
    1. Junttila MJ, Gonzalez M, Lizotte E, Benito B, Vernooy K, Sarkozy A, Huikuri HV, Brugada P, Brugada J, Brugada R. Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. Circulation. 2008;117:1890–1893. doi: 10.1161/CIRCULATIONAHA.107.746495.
    1. Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, Wilde AA, Ackerman MJ. Spectrum and prevalence of mutations from the first 2, 500 consecutive unrelated patients referred for the FAMILION® long QT syndrome genetic test. Heart Rhythm. 2009;6:1297–1303. doi: 10.1016/j.hrthm.2009.05.021.
    1. Kies P, Wichter T, Schäfers M, Paul M, Schäfers KP, Eckardt L, Stegger L, Schulze-Bahr E, Rimoldi O, Breithardt G, Schober O, Camici PG. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation. 2004;110:3017–3022. doi: 10.1161/01.CIR.0000146920.35020.44.
    1. Ko SH, Lenkowski PW, Lee HC, Mounsey JP, Patel MK. Modulation of Nav1.5 by β1-and β3-subunit co-expression in mammalian cells. Pflügers Arch. 2005;449:403–412. doi: 10.1007/s00424-004-1348-4.
    1. Kusano KF, Taniyama M, Nakamura K, Miura D, Banba K, Nagase S, Morita H, Nishii N, Watanabe A, Tada T, Murakami M, Miyaji K, Hiramatsu S, Nakagawa K, Tanaka M, Miura A, Kimura H, Fuke S, Sumita W, Sakuragi S, Urakawa S, Iwasaki J, Ohe T. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol. 2008;51:1169–1175. doi: 10.1016/j.jacc.2007.10.060.
    1. Kyndt F, Probst V, Potet F, Demolombe S, Chevallier JC, Baro I, Moisan JP, Boisseau P, Schott JJ, Escande D, Le Marec H. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation. 2001;104:3081–3086. doi: 10.1161/hc5001.100834.
    1. Lei M, Goddard C, Liu J, Léoni AL, Royer A, Fung SS, Xiao G, Ma A, Zhang H, Charpentier F, Vandenberg JI, Colledge WH, Grace AA, Huang CL. Sinus node dysfunction following targeted disruption of the murine cardiac sodium channel gene Scn5a. J Physiol. 2005;567(Pt 2):387–400. doi: 10.1113/jphysiol.2005.083188.
    1. Lei M, Huang CL, Zhang Y. Genetic Na+ channelopathies and sinus node dysfunction. Prog Biophys Mol Biol. 2008;98:171–178. doi: 10.1016/j.pbiomolbio.2008.10.003.
    1. Li Q, Huang H, Liu G, Lam K, Rutberg J, Green MS, Birnie DH, Lemery R, Chahine M, Gollob MH. Gain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing. Biochem Biophys Res Commun. 2009;380:132–137. doi: 10.1016/j.bbrc.2009.01.052.
    1. London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S, Viswanathan PC, Pfahnl AE, Shang LL, Madhusudanan M, Baty CJ, Lagana S, Aleong R, Gutmann R, Ackerman MJ, McNamara DM, Weiss R, Dudley SC., Jr Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation. 2007;116:2260–2268. doi: 10.1161/CIRCULATIONAHA.107.703330.
    1. Lupoglazoff JM, Cheav T, Baroudi G, Berthet M, Denjoy I, Cauchemez B, Extramiana F, Chahine M, Guicheney P. Homozygous SCN5A mutation in long-QT syndrome with functional two-to-one atrioventricular block. Circ Res. 2001;89:E16–E21. doi: 10.1161/hh1401.095087.
    1. Makielski JC, Farley AL. Na+ current in human ventricle: implications for sodium loading and homeostasis. J Cardiovasc Electrophysiol. 2006;17:S15–S20. doi: 10.1111/j.1540-8167.2006.00380.x.
    1. Makita N. Phenotypic overlap of cardiac sodium channelopathies: individual-specific or mutation-specific? Circ J. 2009;73:810–817. doi: 10.1253/circj.CJ-09-0014.
    1. Makiyama T, Akao M, Shizuta S, Doi T, Nishiyama K, Oka Y, Ohno S, Nishio Y, Tsuji K, Itoh H, Kimura T, Kita T, Horie M. A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. J Am Coll Cardiol. 2008;52:1326–1334. doi: 10.1016/j.jacc.2008.07.013.
    1. Makiyama T, Akao M, Tsuji K, Doi T, Ohno S, Takenaka K, Kobori A, Ninomiya T, Yoshida H, Takano M, Makita N, Yanagisawa F, Higashi Y, Takeyama Y, Kita T, Horie M. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol. 2005;46:2100–2106. doi: 10.1016/j.jacc.2005.08.043.
    1. Mangoni ME, Nargeot J. Genesis and regulation of the heart automaticity. Physiol Rev. 2008;88:919–982. doi: 10.1152/physrev.00018.2007.
    1. Matsuo K, Akahoshi M, Seto S, Yano K. Disappearance of the Brugada-type electrocardiogram after surgical castration: a role for testosterone and an explanation for the male preponderance. Pacing Clin Electrophysiol. 2003;26:1551–1553. doi: 10.1046/j.1460-9592.2003.t01-1-00227.x.
    1. McNair WP, Ku L, Taylor MR, Fain PR, Dao D, Wolfel E, Mestroni L, Familial Cardiomyopathy Registry Research Group SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation. 2004;110:2163–2167. doi: 10.1161/.
    1. Medeiros-Domingo A, Kaku T, Tester DJ, Iturralde-Torres P, Itty A, Ye B, Valdivia C, Ueda K, Canizales-Quinteros S, Tusié-Luna MT, Makielski JC, Ackerman MJ. SCN4B-encoded sodium channel β4 subunit in congenital long-QT syndrome. Circulation. 2007;116:134–142. doi: 10.1161/CIRCULATIONAHA.106.659086.
    1. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? Cardiovasc Res. 2005;67:367–378. doi: 10.1016/j.cardiores.2005.03.005.
    1. Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet. 2008;372:750–763. doi: 10.1016/S0140-6736(08)61307-0.
    1. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;19:1289–1293. doi: 10.1111/j.1540-8167.2008.01246.x.
    1. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, Bottelli G, Cerrone M, Leonardi S. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005;294:2975–2980. doi: 10.1001/jama.294.23.2975.
    1. Nguyen TP, Wang DW, Rhodes TH, George AL., Jr Divergent biophysical defects caused by mutant sodium channels in dilated cardiomyopathy with arrhythmia. Circ Res. 2008;102:364–371. doi: 10.1161/CIRCRESAHA.107.164673.
    1. Noda T, Shimizu W, Taguchi A, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S. ST-segment elevation and ventricular fibrillation without coronary spasm by intracoronary injection of acetylcholine and/or ergonovine maleate in patients with Brugada syndrome. J Am Coll Cardiol. 2002;40:1841–1847. doi: 10.1016/S0735-1097(02)02494-4.
    1. Olson TM, Keating MT. Mapping a cardiomyopathy locus to chromosome 3p22–p25. J Clin Invest. 1996;97:528–532. doi: 10.1172/JCI118445.
    1. Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, Horton SC, Rodeheffer RJ, Anderson JL. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005;293:447–454. doi: 10.1001/jama.293.4.447.
    1. Otagiri T, Kijima K, Osawa M, Ishii K, Makita N, Matoba R, Umetsu K, Hayasaka K. Cardiac ion channel gene mutations in sudden infant death syndrome. Pediatr Res. 2008;64:482–487. doi: 10.1203/PDR.0b013e3181841eca.
    1. Pfahnl AE, Viswanathan PC, Weiss R, Shang LL, Sanyal S, Shusterman V, Kornblit C, London B, Dudley SC., Jr A sodium channel pore mutation causing Brugada syndrome. Heart Rhythm. 2007;4:46–53. doi: 10.1016/j.hrthm.2006.09.031.
    1. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website () Heart Rhythm. 2009;6:1335–1341. doi: 10.1016/j.hrthm.2009.07.002.
    1. Potet F, Chagot B, Anghelescu M, Viswanathan PC, Stepanovic SZ, Kupershmidt S, Chazin WJ, Balser JR. Functional interactions between distinct sodium channel cytoplasmic domains through the action of calmodulin. J Biol Chem. 2009;284:8846–8854. doi: 10.1074/jbc.M806871200.
    1. Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation. 2000;102:945–947.
    1. Probst V, Denjoy I, Meregalli PG, Amirault JC, Sacher F, Mansourati J, Babuty D, Villain E, Victor J, Schott JJ, Lupoglazoff JM, Mabo P, Veltmann C, Jesel L, Chevalier P, Clur SA, Haissaguerre M, Wolpert C, Le Marec H, Wilde AA. Clinical aspects and prognosis of Brugada syndrome in children. Circulation. 2007;115:2042–2048. doi: 10.1161/CIRCULATIONAHA.106.664219.
    1. Probst V, Kyndt F, Potet F, Trochu JN, Mialet G, Demolombe S, Schott JJ, Baró I, Escande D, Le Marec H. Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenègre disease. J Am Coll Cardiol. 2003;41:643–652. doi: 10.1016/S0735-1097(02)02864-4.
    1. Rivolta I, Abriel H, Tateyama M, Liu H, Memmi M, Vardas P, Napolitano C, Priori SG, Kass RS. Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. J Biol Chem. 2001;276:30623–30630. doi: 10.1074/jbc.M104471200.
    1. Royer A, van Veen TA, Le Bouter S, Marionneau C, Griol-Charhbili V, Léoni AL, Steenman M, van Rijen HV, Demolombe S, Goddard CA, Richer C, Escoubet B, Jarry-Guichard T, Colledge WH, Gros D, de Bakker JM, Grace AA, Escande D, Charpentier F. Mouse model of SCN5A-linked hereditary Lenègre's disease: age-related conduction slowing and myocardial fibrosis. Circulation. 2005;111:1738–1746. doi: 10.1161/01.CIR.0000160853.19867.61.
    1. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation. 2007;116:1137–1144. doi: 10.1161/CIRCULATIONAHA.107.707877.
    1. Schott JJ, Alshinawi C, Kyndt F, Probst V, Hoorntje TM, Hulsbeek M, Wilde AA, Escande D, Mannens MM, Le Marec H. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet. 1999;23:20–21. doi: 10.1038/12618.
    1. Schwartz PJ, Priori SG, Dumaine R, Napolitano C, Antzelevitch C, Stramba-Badiale M, Richard TA, Berti MR, Bloise R. A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med. 2000;343:262–267. doi: 10.1056/NEJM200007273430405.
    1. Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantù F, Towbin JA, Keating MT, Hammoude H, Brown AM, Chen LS. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92:3381–3386.
    1. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89–95.
    1. Schwartz PJ, Stramba-Badiale M, Segantini A, Austoni P, Bosi G, Giorgetti R, Grancini F, Marni ED, Perticone F, Rosti D, Salice P. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med. 1998;338:1709–1714. doi: 10.1056/NEJM199806113382401.
    1. Smits JP, Eckardt L, Probst V, Bezzina CR, Schott JJ, Remme CA, Haverkamp W, Breithardt G, Escande D, Schulze-Bahr E, LeMarec H, Wilde AA. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol. 2002;40:350–356. doi: 10.1016/S0735-1097(02)01962-9.
    1. Smits JP, Koopmann TT, Wilders R, Veldkamp MW, Opthof T, Bhuiyan ZA, Mannens MM, Balser JR, Tan HL, Bezzina CR, Wilde AA. A mutation in the human cardiac sodium channel (E161K) contributes to sick sinus syndrome, conduction disease and Brugada syndrome in two families. J Mol Cell Cardiol. 2005;38:969–981. doi: 10.1016/j.yjmcc.2005.02.024.
    1. Shimizu W, Matsuo K, Kokubo Y, Satomi K, Kurita T, Noda T, Nagaya N, Suyama K, Aihara N, Kamakura S, Inamoto N, Akahoshi M, Tomoike H. Sex hormone and gender difference—role of testosterone on male predominance in Brugada syndrome. J Cardiovasc Electrophysiol. 2007;18:415–421. doi: 10.1111/j.1540-8167.2006.00743.x.
    1. Tan HL, Bink-Boelkens MT, Bezzina CR, Viswanathan PC, Beaufort-Krol GC, van Tintelen PJ, van den Berg MP, Wilde AA, Balser JR. A sodium-channel mutation causes isolated cardiac conduction disease. Nature. 2001;409:1043–1047. doi: 10.1038/35059090.
    1. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2:507–517. doi: 10.1016/j.hrthm.2005.01.020.
    1. Ueda K, Valdivia C, Medeiros-Domingo A, Tester DJ, Vatta M, Farrugia G, Ackerman MJ, Makielski JC. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci USA. 2008;105:9355–9360. doi: 10.1073/pnas.0801294105.
    1. Valdivia CR, Tester DJ, Rok BA, Porter CB, Munger TM, Jahangir A, Makielski JC, Ackerman MJ. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovasc Res. 2004;62:53–62. doi: 10.1016/j.cardiores.2004.01.022.
    1. Valdivia CR, Ueda K, Ackerman MJ, Makielski JC. GPD1L links redox state to cardiac excitability by PKC-dependent phosphorylation of the sodium channel SCN5A. Am J Physiol, Heart Circ Physiol. 2009;297:H1446–H1452. doi: 10.1152/ajpheart.00513.2009.
    1. Van Norstrand DW, Valdivia CR, Tester DJ, Ueda K, London B, Makielski JC, Ackerman MJ. Molecular and functional characterization of novel glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) mutations in sudden infant death syndrome. Circulation. 2007;116:2253–2259. doi: 10.1161/CIRCULATIONAHA.107.704627.
    1. Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, Taylor EW, Tester DJ, Balijepalli RC, Foell JD, Li Z, Kamp TJ, Towbin JA. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation. 2006;114:2104–2112. doi: 10.1161/CIRCULATIONAHA.106.635268.
    1. Veldkamp MW, Viswanathan PC, Bezzina C, Baartscheer A, Wilde AA, Balser JR. Two distinct congenital arrhythmias evoked by a multidysfunctional Na+ channel. Circ Res. 2000;86:E91–E97.
    1. Veldkamp MW, Wilders R, Baartscheer A, Zegers JG, Bezzina CR, Wilde AA. Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ Res. 2003;92:976–983. doi: 10.1161/01.RES.0000069689.09869.A8.
    1. Verkerk AO, Wilders R, van Borren MM, Tan HL. Is sodium current present in human sinoatrial node cells? Int J Biol Sci. 2009;5:201–204.
    1. Wang DW, Desai RR, Crotti L, Arnestad M, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Rognum T, Schwartz PJ, George AL., Jr Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation. 2007;115:368–376. doi: 10.1161/CIRCULATIONAHA.106.646513.
    1. Wang DW, Yazawa K, George AL, Jr, Bennett PB. Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome. Proc Natl Acad Sci USA. 1996;93:13200–13205. doi: 10.1073/pnas.93.23.13200.
    1. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805–811. doi: 10.1016/0092-8674(95)90359-3.
    1. Watanabe H, Darbar D, Kaiser DW, Jiramongkolchai K, Chopra S, Donahue BS, Kannankeril PJ, Roden DM. Mutations in sodium channel β1- and β2-subunits associated with atrial fibrillation. Circ Arrhythmia Electrophysiol. 2009;2:268–275. doi: 10.1161/CIRCEP.108.779181.
    1. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ, Demolombe S, Probst V, Anselme F, Escande D, Wiesfeld AC, Pfeufer A, Kääb S, Wichmann HE, Hasdemir C, Aizawa Y, Wilde AA, Roden DM, Bezzina CR. Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008;118:2260–2268.
    1. Wedekind H, Smits JP, Schulze-Bahr E, Arnold R, Veldkamp MW, Bajanowski T, Borggrefe M, Brinkmann B, Warnecke I, Funke H, Bhuiyan ZA, Wilde AA, Breithardt G, Haverkamp W. De novo mutation in the SCN5A gene associated with early onset of sudden infant death. Circulation. 2001;104:1158–1164. doi: 10.1161/hc3501.095361.
    1. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RN, Kass RS, Nademanee K, Priori SG, Towbin JA, Study Group on the Molecular Basis of Arrhythmias of the European Society of Cardiology Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation. 2002;106:2514–2519. doi: 10.1161/01.CIR.0000034169.45752.4A.
    1. Yan GX, Wu Y, Liu T, Wang J, Marinchak RA, Kowey PR. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation. 2001;103:2851–2856.
    1. Zimmer T, Surber R. SCN5A channelopathies—an update on mutations and mechanisms. Prog Biophys Mol Biol. 2008;98:120–136. doi: 10.1016/j.pbiomolbio.2008.10.005.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner